March 7th 2016
The level of vitamin D in a patient’s blood could serve as a biomarker for an aggressive form of prostate cancer, especially in men who are considering active surveillance for the disease.
February 24th 2016
Galeterone is being explored in the ARMOR 3-SV study, in which men with progressive metastatic disease who have received prior androgen deprivation therapy are randomized to receive either galeterone or enzalutamide.
February 23rd 2016
The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.
February 9th 2016
Being the largest private practice urology center in Kentucky has its advantages, said Ganesh Rao, MD, president of First Urology, PSC, in Louisville.
February 5th 2016
With the approval of a dual checkpoint blockade treatment in melanoma, researchers hope to have similar success in a phase III trial that combines a PD-L1 inhibitor and CTLA-4 antibody in patients with non–small cell lung cancer.
February 2nd 2016
The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance, there are many options to consider.
February 1st 2016
Using a genomic classifier that identifies men who are at highest risk for developing metastasis after prostatectomy and salvage radiation therapy can help clinicians distinguish which patients would benefit from more aggressive follow-up therapy, according to recent research.
January 13th 2016
Researchers are combining the novel CD20-targeting agent ublituximab (TG-1101) with ibrutinib to determine whether the regimen can improve outcomes in CLL, particularly for patients whose disease has high-risk features.
January 6th 2016
PD-1 and PD-L1 inhibitors, including nivolumab, atezolizumab, and avelumab, will likely play a major role as the backbone of combination therapy for patients with renal cell carcinoma (RCC).
Clinical studies suggest that PARP inhibitors are highly efficacious in patients with metastatic castration-resistant prostate cancer with these alternations in DNA repair genes.
January 4th 2016
The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.
December 15th 2015
When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.
December 2nd 2015
Recent trends suggest a shift away from radiation therapy and more toward radical prostatectomy for patients with high-risk prostate cancer.
November 28th 2015
The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.
November 26th 2015
A test called the Stockholm 3 (STHLM3) has been shown to detect aggressive prostate cancer cancer earlier, reduce the number of false positives, and decrease the number of unnecessary biopsies.
November 21st 2015
Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.
November 7th 2015
With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.
November 6th 2015
Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.
November 4th 2015
Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.
October 24th 2015
Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.